Trinity Biotech plc (NASDAQ:TRIB) Short Interest Update

Trinity Biotech plc (NASDAQ:TRIB) was the recipient of a significant drop in short interest during the month of March. As of March 15th, there was short interest totalling 4,300 shares, a drop of 71.9% from the February 29th total of 15,300 shares. Approximately 0.1% of the company’s shares are short sold. Based on an average daily volume of 93,600 shares, the short-interest ratio is currently 0.0 days.

Institutional Investors Weigh In On Trinity Biotech

Several large investors have recently bought and sold shares of the business. Renaissance Technologies LLC increased its holdings in Trinity Biotech by 2.4% in the 2nd quarter. Renaissance Technologies LLC now owns 1,503,336 shares of the company’s stock worth $1,842,000 after buying an additional 34,900 shares in the last quarter. Whitefort Capital Management LP grew its stake in shares of Trinity Biotech by 1,067.8% during the 1st quarter. Whitefort Capital Management LP now owns 409,517 shares of the company’s stock valued at $434,000 after purchasing an additional 374,449 shares during the period. Virtu Financial LLC bought a new stake in shares of Trinity Biotech during the 1st quarter valued at about $40,000. Finally, Atria Wealth Solutions Inc. grew its stake in shares of Trinity Biotech by 38.9% during the 4th quarter. Atria Wealth Solutions Inc. now owns 34,300 shares of the company’s stock valued at $34,000 after purchasing an additional 9,600 shares during the period. 78.97% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, StockNews.com initiated coverage on Trinity Biotech in a research note on Saturday, March 23rd. They issued a “buy” rating for the company.

Trinity Biotech Stock Down 2.0 %

TRIB opened at $1.98 on Thursday. The stock has a 50-day moving average price of $2.27 and a 200-day moving average price of $2.48. Trinity Biotech has a 1 year low of $1.85 and a 1 year high of $6.20.

Trinity Biotech (NASDAQ:TRIB) last posted its quarterly earnings results on Wednesday, January 31st. The company reported ($0.90) earnings per share (EPS) for the quarter. The firm had revenue of $14.68 million during the quarter. As a group, equities research analysts expect that Trinity Biotech will post -2.95 EPS for the current fiscal year.

About Trinity Biotech

Trinity Biotech plc acquires, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.